bluebird reports additional Phase II/III data for Lenti-D gene therapy in childhood CALD

In October, bluebird bio Inc. (NASDAQ:BLUE) reported additional data from 17 boys with cerebral adrenoleukodystrophy (CALD) in the Phase II/III Starbeam (ALD-102) trial showing that Lenti-D led

Read the full 276 word article

User Sign In